Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for life-threatening medical conditions. The company's lead product candidate, transcrocetinate sodium (TSC), aims to enhance oxygen delivery to hypoxic tissues, addressing complications associated with various severe health issues. TSC is currently in Phase III clinical trials for glioblastoma multiforme and Phase II trials for metastatic brain cancer and acute stroke. Additionally, Diffusion is working on RES-529, a PI3K/Akt/mTOR pathway inhibitor that has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development for oncology applications, primarily targeting glioblastoma. The company also has a research collaboration with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to explore TSC's efficacy in patients suffering from acute respiratory distress syndrome related to COVID-19. Founded in 2001, Diffusion Pharmaceuticals is dedicated to addressing critical health challenges through its advanced therapeutic candidates.